15 April 2009 - Wafergen Biosystems has signed a definitive agreement to sell redeemable convertible preferred shares in the company's wholly owned Malaysian subsidiary.
Under the terms of the agreement, Wafergen has agreed to sell 666,666 redeemable convertible preferred Series B shares in the subsidiary for gross proceeds of USD1.5m, which are expected to be used to manufacture and commercialise the company's Smartchip real-time PCR system.
